Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naftali Bechar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Oncology Practice|June 12, 2010
Basic steps to building a research programAllison Baer, Naftali Bechar, Gary Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology GroupShadia Jalal, Pablo Bedano, Lawrence Einhorn, et al.
Oncology|May 11, 2012
A pilot study of long-acting octreotide for symptomatic malignant ascitesAminah Jatoi, Jorge J Nieva, Rui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Oncology Practice|June 12, 2010
Basic steps to building a research programAllison Baer, Naftali Bechar, Gary Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology GroupShadia Jalal, Pablo Bedano, Lawrence Einhorn, et al.
Oncology|May 11, 2012
A pilot study of long-acting octreotide for symptomatic malignant ascitesAminah Jatoi, Jorge J Nieva, Rui Qin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Pageof 1